Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Sputum after Challenge with Inhaled Lipopolysaccharide (LPS).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2011
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 09 Aug 2011 New trial record